Methods to modulate conditions mediated by the CXCR4 receptor

Details Methods to modulate conditions mediated by the CXCR4 receptor Methods to modulate conditions mediated by the CXCR4 receptor

2004-11-17

2008-08-19

Coleman, Brenda L (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S183000, C540S474000

Reexamination Certificate

active

07414065

ABSTRACT:
The present invention is drawn to novel antiviral compounds, pharmaceutical compositions and their use. More specifically this invention is drawn to derivatives of monocyclic polyamines which have activity in standard tests against HIV- or FIV-infected cells as well as other biological activity related to binding of ligands to chemokine receptors that mediate a number of mammalian embryonic developmental processes.

REFERENCES:
patent: 5021409 (1991-06-01), Murrer
patent: 5583131 (1996-12-01), Bridger
patent: 5698546 (1997-12-01), Bridger
patent: 5817807 (1998-10-01), Bridger
patent: 6365583 (2002-04-01), MacFarland
patent: 2001/0033841 (2001-10-01), Luster
patent: 2002/0039993 (2002-04-01), Winchester
patent: 2004/0209837 (2004-10-01), Kishimoto et al.
patent: 2006/0194776 (2006-08-01), Losordo et al.
patent: 0 434 385 (1991-06-01), None
patent: 0 747 368 (1996-12-01), None
patent: 1 072 273 (2001-01-01), None
patent: WO-92/16494 (1992-10-01), None
patent: WO-93/12096 (1993-06-01), None
patent: WO-95/18808 (1995-07-01), None
patent: WO-99/47158 (1999-09-01), None
patent: WO-99/65507 (1999-12-01), None
patent: WO-00/02870 (2000-01-01), None
patent: WO-00/09152 (2000-02-01), None
patent: WO-00/45814 (2000-08-01), None
Arenburg et al., J. Leukocyte Biol. 62(5):554-562 (1997).
Bertolini et al., Cancer Research (2002) 62:3106-3112.
Bleul et al., “The Lymphocyte Chemoattractant SDF-1 is a Ligand for LESTR/Fusin and Blocks HIV-1 Entry”, Nature, 382(6594): 829-832 (1996).
Boshoff et al., “Angiogenic and HIV-Inhibitory Functions of KSHV-Encoded Chemokines”, Science, 278(5336):290-294 (1997).
Bradstock et al., Leukemia (2000) 14:882-888.
Bridger et al., “Synthesis and Structure-Activity Relationships of Phenylenebis (methylene)- Linked Bis- Tetraazamacrocytes That Inhibit HIV Replication. Effects of Macrocyclic Ring Size and Substituents on the Aromatic Linker”, J. Med. Chem. 38:366-378 (1995).
Bridger et al., “Synthesis and Structure-Activity Relationships of Phenylenebis (methylene)- Linked Bis-Tetraazamacrocytes That Inhibit HIV Replication. 2. Effect of Heteroaromatic Linkers on the Activity of Bicyclams”, J. Med. Chem., 39(1):109-119 (1996).
Ponath et al., “Chemokine Receptor Antagonists: Novel Therapeutics for Inflammation and AIDS”, Exp. Opin. Invest. Drugs, 7:1-18 (1998).
Rempel et al., Clinical Cancer Research (2000) 6:102-111.
Robledo et al., The Journal of Biological Chemistry (2001) 276(48):45098-45105.
Sanz-Rodriguez et al., Blood (2001) 97(2):346-351.
Schols et al., “Inhibition of T-Tropic HIV Strains by Selective Antagonization of the Chemokine Receptor CXCR4”, J. Exp. Med., 186(8):1383-88 (1997).
Schols et al., “Bycyclams, A Class of Potent Anti-HIV Agents, are Targeted at the HIV Coreceptor Fusin/CXCR-4”, Antiviral Research, 35:147-156 (1997).
Scotton et al., Cancer Research (2001) 61:4961-4965.
Shen et al., Experimental Hematology (2001) 29:1439-1447.
Tachibana et al., “The Chemokine Receptor CXCR4 is Essential for Vascularization of the Gastrointestinal Tract”, Nature, 393:591-94 (1998).
Wyatt et al., “The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens”, Science, 280:1884-88 (1998).
Zou et al., “Functions of the Chemokine Receptor CXCR4 in Haematopoiesis and In Cerebellar Development”, Nature, 393:595-99 (1998).
Burger et al., Blood (2000) 96(8):2655-2663.
Burger et al., Blood (1999) 94(11):3658-3667.
Carroll et al. “Differential Regulation of HIV-1 Fusion Cofactor Expression by CD28 Costimulation of CD4+ T Cells”, Science, 276(5310):273-276 (1997).
Chemical Abstracts, 113:40649 (1990).
Chemical Abstracts, 111:190197 (1987).
Chemical Abstracts, 123:56538 (1994).
De Bont et al., Cancer Research (2001) 61:7654-7659.
De Clerco et al., “Highly Potent and Selective Inhibition of Human Immunodeficiency Virus by the Byclam Derivative JM3100”, Antimicrobial Agents & Chemotherapy, 38(4):668-674 (1994).
Devries et al., Seminars in Immunology (1999) 11:95-104.
Donzella et al., “AMD3100, A Small Molecule Inhibitor of HIV-1 Entry Via the CXCR4 Co-Receptor”, Nature Medicine, 4(1):72-77 (1998).
Durig et al., Leukemia (2001) 15:752-756.
Fukuyama et al., “2- and 4-Nitrobenzenesulfonamides: Exceptionally Versatile Means for Preparation of Secondary Amines and Protection of Amines”, Tetrahedron Letters, 36(36):6373-74 (1995).
Gazitt and Liu, Stem Cells (2001) 19:37-45.
Geminder et al., The Journal of Immunology (2001) 167:4747-4757.
Gupta et al., “Chemokine Receptors In Human Endothelial Cells”, J. Biological Chem., 273(7):4282-87 (1998).
Hesselgesser et al., J. of Biol. Chem. (1998) 273(25):15687-15692.
Hoxie et al., “CD4-Independent Infection by HIV-2 is Mediated by Fusin/CXCR4”, Cell, 87:745-756 (1996).
International Search Report for PCT/CA99/00619, Oct. 1999.
Joao et al. “Quantitative Structural Activity Relationship Study of Bis-Tetraazacyclic Compounds. A Novel Series of HIV-1 and HIV-2 Inhibitors”, J. Med. Chem. 38:3865-73 (1995).
Koshiba et al., Clinical Cancer Research (2000) 6:3530-3535.
Lagneaux et al., Poster session: Bone Marrow Stroma and Marrow Failure, Saturday, Jul. 6, 2002, Abstract #72.
Leff, “Besides Aiding AIDS Entry, Receptor Honchos Fetal Growth of Brain, Gut, Blood Systems”, Bioworld Today, 9:111 (1998).
Libura et al., Blood (2002) 100(7):2597-2606.
Martin et al., Helv Chem. Chem. Soc. 73:149-153 (1990).
Miedema et al., “Changing Virus-Host Interactions in the Course of HIV-1 Infection”, Immunological Reviews, 140:35-72 (1994).
Mohle et al., Blood (1998) 91(12):4523-4530.
Moore et al., Journal of Investigative Medicine (1998) 46(4):113-120.
Morphy et al., “Towards Tumour Targeting with Copper-Radiolabelled Macrocycle-Antibody Conjugates: Synthesis, Antibody Linkage, and Complexation Behaviour”, J. Chem. Soc. Perkin Trans., 2:573-85 (1990).
Muller et al., Nature (2001) 410:50-56.
Oberlin et al. “The CXC Chemokine SDF-1 is the Ligand for Lestr/Fusin and Prevents.
Hesselgesser et al., Journal of Biological Chemistry (1998) 273(25):15687-15692.
Horuk et al., Chemokine Receptors, Cytokine and Growth Factor Reviews (2001) 12(4):313-355.

Affiliated with

Also associated with

Rating

Methods to modulate conditions mediated by the CXCR4 receptor does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods to modulate conditions mediated by the CXCR4 receptor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods to modulate conditions mediated by the CXCR4 receptor will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4002394